Glycotope GmbH Information

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. We combine expertise in glycobiology and know-how in antibody development to advance first-in-class antibody-based therapeutics for (immuno)-oncology. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins. Glycotope has to date discovered in excess of 200 GlycoTargets with several antibodies against selected targets under development.